RxDoctor Payments Data

Cindy Jacob, MD

Family Medicine · Katy, TXNPI 1174747661

Payments from drug & device makers

$10,159in general payments, 2019–2025

Across 565 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • Pfizer$695
  • Boehringer Ingelheim$691
  • Amgen$534
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$10,05099%
  • Education$1091%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,159 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$27,031
Medicare patients
95
Services billed
449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide61$80,453
FarxigaDapagliflozin Propanediol69$73,400
OzempicSemaglutide50$68,603
JanuviaSitagliptin Phosphate45$56,395
TrulicityDulaglutide35$44,064
EliquisApixaban37$41,871
RybelsusSemaglutide21$37,654
LinzessLinaclotide31$34,135
Nurtec OdtRimegepant Sulfate19$32,092
JardianceEmpagliflozin32$29,675
XareltoRivaroxaban17$22,824
MyrbetriqMirabegron20$20,941
Repatha SureclickEvolocumab19$16,163
VascepaIcosapent Ethyl19$15,950
Combivent RespimatIpratropium/Albuterol Sulfate11$7,462

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$325$124,51696 claims
Novo NordiskOzempic, Rybelsus, Novolog Mix 70-30$1,449$107,20683 claims
PfizerEliquis, Nurtec Odt, Dilantin$695$76,86268 claims
AstraZenecaFarxiga$1,238$73,40069 claims
MerckJanuvia$175$56,39545 claims
Boehringer IngelheimJardiance, Combivent Respimat$691$37,13743 claims
AbbVieLinzess$1,225$34,13531 claims
Johnson & JohnsonXarelto$57$22,82417 claims
Astellas Pharma US IncMyrbetriq$148$20,94120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Katy

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →